FDA to discuss imatinib for PAH
FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Sept. 14 to discuss an NDA from Novartis AG (NYSE:NVS; SIX:NOVN) for imatinib to treat pulmonary arterial hypertension (PAH). The PDUFA date is not disclosed. Novartis submitted the..
Original Article: FDA to discuss imatinib for PAHNEXT ARTICLE